PCRX — Pacira BioSciences, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1396814 ·
Last close
$36.48
Market Cap
$1.46B
52W High
$36.67
52W Low
$18.80
ADV30
2,230,807
Next earnings
2026-11-05

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 176,653,000 139,420,000 16,542,000 28,521,000 1,202,639,000 246,957,000 490,318,000
Jun 2026 192,399,000 148,235,000 11,861,000 4,653,000 1,243,978,000 205,875,000 572,002,000
Mar 2026 177,376,000 140,963,000 4,625,000 2,916,000 1,208,534,000 144,306,000 554,641,000
Dec 2025 196,873,000 156,574,000 -10,921,000 1,637,000 1,264,917,000 158,545,000 571,806,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$187,663,000
Investing CF
$94,147,000
Financing CF
$-376,176,000
CapEx
$-8,148,000
Dividends Paid
—
Buybacks
$-148,334,000
EPS Diluted TTM
$0.35
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-191,753,000
Inventory
$134,575,000
Receivables
$132,420,000
ST Investments
$45,156,000
EBIT TTM
$30,952,000
Pretax Income TTM
$17,648,000
Interest Exp TTM
$13,304,000
Analysts
7

Yahoo Snapshot (yfinance, live)

Total Revenue
$743,300,992
EBITDA
$133,044,000
Free Cash Flow
$198,565,872
Enterprise Value
$1,505,351,424
Total Cash
$295,576,992
Total Debt
$340,280,000
Shares Out
39,912,226
Trailing EPS
$0.93
Book Value
$17.85
ROE
5.2%
ROA
2.5%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 726,411,000 19,191,000 7,034,000 1,264,917,000 571,806,000 693,111,000 151,994,000
Dec 2024 700,966,000 89,872,000 -99,560,000 1,553,516,000 775,168,000 778,348,000 189,389,000
Dec 2023 674,978,000 87,675,000 41,955,000 1,574,386,000 704,256,000 870,130,000 154,649,000
Dec 2022 666,823,000 60,024,000 15,909,000 1,681,200,000 906,190,000 775,010,000 145,274,000

TTM Snapshot

Revenues TTM
$746,164,000
NetIncome TTM
$14,638,000
OpCashFlow TTM
—
Assets (Latest)
$1,243,978,000
Forward EPS
$3.46

Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)

max pain strike: $32.50 · spot: $36.48 · call volume: 440 · put volume: 50
Expected Move to 2027-01-15: ±$0.55 (1.51%) — implied range $35.93 – $37.03 · ATM straddle on $37.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
QURE uniQure N.V. $1.46B $20.78 —
URGN UroGen Pharma Ltd. $1.47B $29.87 —
KRSA Korsana Biosciences, Inc. $1.48B $32.50 —
RAPP Rapport Therapeutics, Inc. $1.41B $23.76 —
DMRA Damora Therapeutics, Inc. $1.40B $22.56 —

News headlines (Yahoo Finance, 1h cache)

Viatris Completes Acquisition of Pacira BioSciences
2026-11-17 13:50 · Yahoo
Viatris Announces Commencement of Tender Offer to Acquire Pacira BioSciences, Inc.
2026-10-30 12:40 · Yahoo
Pacira BioSciences (PCRX) Reports Next Week: Wall Street Expects Earnings Growth
2026-10-29 13:00 · Yahoo
Pacira BioSciences (PCRX) Stock Gets Fair Value Boost After Viatris Deal Framing
2026-10-23 16:13 · Yahoo
Pacira Biosciences' Acquisition by Viatris Unlikely to See Superior Bid, RBC Says
2026-10-09 15:23 · Yahoo
Viatris (VTRS) Buys Pacira As Fair Value Stays In Focus
2026-10-09 06:09 · Yahoo
Viatris (VTRS) Stock May Be Below Fair Value Despite A $1.65B Deal
2026-11-08 01:15 · Yahoo
Viatris Inc. Q3 2026 Earnings Call Summary
2026-11-05 22:41 · Yahoo
Viatris Reports Third-Quarter 2026 Financial Results
2026-11-05 11:59 · Yahoo
Viatris Announces Quarterly Dividend
2026-11-04 11:59 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.